ES2590340T3 - SlpA como herramienta para la tecnología recombinante de proteínas y enzimas - Google Patents

SlpA como herramienta para la tecnología recombinante de proteínas y enzimas Download PDF

Info

Publication number
ES2590340T3
ES2590340T3 ES09006933.7T ES09006933T ES2590340T3 ES 2590340 T3 ES2590340 T3 ES 2590340T3 ES 09006933 T ES09006933 T ES 09006933T ES 2590340 T3 ES2590340 T3 ES 2590340T3
Authority
ES
Spain
Prior art keywords
slpa
polypeptide
protein
prot
target
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09006933.7T
Other languages
English (en)
Spanish (es)
Inventor
Elke Faatz
Peter Schaarschmidt
Urban Schmitt
Christian Scholz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2590340T3 publication Critical patent/ES2590340T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
ES09006933.7T 2008-05-26 2009-05-25 SlpA como herramienta para la tecnología recombinante de proteínas y enzimas Active ES2590340T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08009537 2008-05-26
EP08009537A EP2127678A1 (en) 2008-05-26 2008-05-26 SlpA as a tool for recombinant protein and enzyme technology

Publications (1)

Publication Number Publication Date
ES2590340T3 true ES2590340T3 (es) 2016-11-21

Family

ID=39590486

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09006933.7T Active ES2590340T3 (es) 2008-05-26 2009-05-25 SlpA como herramienta para la tecnología recombinante de proteínas y enzimas

Country Status (6)

Country Link
US (2) US8263086B2 (enExample)
EP (2) EP2127678A1 (enExample)
JP (1) JP5611540B2 (enExample)
CN (1) CN101591665B (enExample)
CA (1) CA2667177C (enExample)
ES (1) ES2590340T3 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2617731A1 (en) * 2012-01-19 2013-07-24 Roche Diagnostics GmbH Soluble immunoreactive Treponema pallidum TpN47 antigens
EP2706115A1 (en) * 2012-09-06 2014-03-12 Roche Diagnostics GmbH Chaperone-chaperone fusion polypeptides for reduction of interference and stabilization of immunoassays
EP2827146A1 (en) 2013-07-18 2015-01-21 Roche Diagnostics GmbH Vibrio cholerae lipoprotein 15 (Lp15) variants as anti-interference additive in TpN17-based immunoassays for detection of anti-Treponema antibodies
EP3084441B1 (en) * 2013-12-19 2018-03-28 Intervet International B.V. Improved diagnostic test for csfv antibodies
EP2913338A1 (en) * 2014-02-28 2015-09-02 Roche Diagniostics GmbH Soluable and immunoreactive variants of HTLV capsid antigen p24
WO2016064643A1 (en) * 2014-10-24 2016-04-28 University Of Florida Research Foundation, Incorporated Lactobacillus acidophilus surface layer protein a (slpa) as a therapeutic agent for the treatment of inflammatory diseases
WO2016089782A1 (en) 2014-12-01 2016-06-09 Pfenex Inc. Fusion partners for peptide production
BR112018072042A2 (pt) 2016-05-31 2019-03-12 Hoffmann La Roche métodos de detecção de polipeptídeo e de processamento prévio de amostras, reagente de processamento prévio, kit de detecção de hcv e uso de composição
EP3465216B1 (en) 2016-05-31 2020-04-08 Roche Diagnostics GmbH Pretreatment method for rapid detection of hcv core antigen
JP7068323B2 (ja) 2017-02-02 2022-05-16 エフ．ホフマン－ラ ロシュ アーゲー 少なくとも２種のペグ化された分析物特異的結合剤を使用する免疫アッセイ
JP7389740B2 (ja) * 2017-07-27 2023-11-30 エフ． ホフマン－ラ ロシュ アーゲー Ｈｃｖ抗原のマルチエピトープ融合タンパク質およびその使用
CA3120482A1 (en) * 2018-11-19 2020-05-28 Bioaster Methods and reagents for multiplex binding experiments
WO2023060116A2 (en) * 2021-10-05 2023-04-13 Viro Research, Llc Herpes simplex virus types 1 and 2 lateral flow assay
CN122138968A (zh) 2023-11-09 2026-06-02 罗氏诊断公司 用于标记的转谷氨酰胺酶底物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7157089B1 (en) * 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
US5989868A (en) 1997-09-12 1999-11-23 The Board Of Regents Of The University Of Oklahoma Fusion protein systems designed to increase soluble cytoplasmic expression of heterologous proteins in esherichia coli
ATE522603T1 (de) 2001-06-22 2011-09-15 Hoffmann La Roche Löslicher komplex, der retrovirale oberflächen- glykoproteine und fkpa oder slyd enthält
JP4871960B2 (ja) 2006-01-03 2012-02-08 エフ．ホフマン−ラ ロシュ アーゲー 優れたシャペロン活性およびフォールディング活性を有するキメラ融合タンパク質

Also Published As

Publication number Publication date
CN101591665B (zh) 2016-08-31
EP2127679A1 (en) 2009-12-02
JP5611540B2 (ja) 2014-10-22
EP2127679B1 (en) 2016-06-29
CA2667177A1 (en) 2009-11-26
US20090291892A1 (en) 2009-11-26
CN101591665A (zh) 2009-12-02
HK1138620A1 (zh) 2010-08-27
JP2009284902A (ja) 2009-12-10
US8263086B2 (en) 2012-09-11
US8790659B2 (en) 2014-07-29
US20120308994A1 (en) 2012-12-06
CA2667177C (en) 2017-08-15
EP2127678A1 (en) 2009-12-02

Similar Documents

Publication Publication Date Title
JP5611540B2 (ja) 組換えタンパク質および酵素技術のためのツールとしてのＳｌｐＡ
ES2333108T3 (es) Utilizacion de chaperonas fkbp como herramienta de expresion.
ES2368624T3 (es) Detección de infecciones primarias por patógenos.
ES2375863T3 (es) Prote�?na de fusión quimérica con actividades de chaperón y de plegamiento superiores.
EP3390424B1 (en) Fkbp domain with transglutaminase recognition site
US8551696B2 (en) Rubella E1 envelope protein variants and their use in detection of anti-rubella antibodies
EP1780282B1 (en) Recombinant expression of Rubella E1 envelope protein variants as chaperone fusion-proteins, and their use in the detection of anti-Rubella antibodies
ES2356383T3 (es) Expresión recombinante de variantes de proteína de cubierta de rubeola e1 como proteínas de fusión chaperonas, y utilización de las mismas en la detección de anticuerpos anti-rubeola.
HK1138620B (en) Slpa as a tool for recombinant protein and enzyme technology
HK1148026B (en) Novel rubella e1 envelope protein variants and their use in the detection of antirubella antibodies